russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2014-4-ENG-22-27russjcardiol-602Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESБЕЗОПАСНОСТЬ ТИРОФИБАНА ДЛЯ ПАЦИЕНТОВ С ОСТРЫМ ИШЕМИЧЕСКИМ ИНСУЛЬТОМ В РУТИННОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕSAFETY OF TIROFIBAN FOR PATIENTS WITH ACUTE ISCHEMIC STROKE IN ROUTINE CLINICAL PRACTICEZhangYan-JunZhangYan-Jun

Department of Geriatrics, People’s Hospital of Zhengzhou, Zhengzhou 450003, China. Tel: 86–0371–67077323

yjlqcn@163.comLiuQingLiuQingZhanQinZhanQinLiQiongLiQiongDepartment of Geriatrics, People’s Hospital of Zhengzhou, Zhengzhou, China20142804201404-ENG2227Copyright © Zhang Y., Liu Q., Zhan Q., Li Q., 20142014Zhang Y., Liu Q., Zhan Q., Li Q.Zhang Y., Liu Q., Zhan Q., Li Q.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/602Цель

Цель. Данная работа направлена на исследование безопасности применения одного тирофибана и в сочетании с различными препаратами в острый период ишемического инсульта (ОИИ).

Материал и методы

Материал и методы. 120 пациентов с ОИИ были включены в это исследование. Они были разделены на 3 группы: Группа А (тирофибан, n=68), группа б (тирофибан плюс тромболитическая терапия, n=26), и группа C (тирофибан плюс сопутствующее лечение, n=26). Факторы риска, степень тяжести инсульта, первичное обследование, схемы лечения, осложнений и долгосрочные результаты были проанализированы.

Результаты

Результаты. Восемь пациентов (6,7%) в группе, у 6 (23,1%) в группе B и 2 пациентов (7,7%) в группе C, были кровотечения во время или после лечения. Шестнадцать пациентов (6 в группе А, 8-в группе B и 2 в группе C) умерли во время госпитализации. Уровень смертности составил 13,3% (8,8% для группы А, 30,7% для группы B и 7,7% для группы C, соответственно) в фазе обострения. Благоприятный исход (mRS 0–2) в первые три месяца после инсульта наблюдался только в 43,3% пациентов (44,1% в группе А, 46,7% в группе В и 36,4% в группе C). Средний Barthel index был 72,3 в группе А, 84,4 в группе B и 56,8 группы C (Общая оценка: 71,0).

Вывод

Вывод. Лечение инсультов с применением тирофибана безопасно при ОИИ. Большие рандомизированные контролируемые испытания будут необходимы в будущем для уменьшения незначительных кровотечений как осложнений терапии тирофибаном.

Aim

Aim. This work aims to study the safety of tirofiban alone and in combination with various treatments in acute ischemic stroke (AIS).

Material and methods

Material and methods. 120 AIS patients were included in this study. There were 3 groups as below: Group A (tirofiban alone, n=68), Group B (tirofiban plus thrombolytic therapy, n=26), and Group C (tirofiban plus bridging therapy, n=26). Risk factors, stroke severity, initial imaging, treatment regimens, complications and longterm outcomes were analyzed.

Results

Results. Eight patients (6,7%) in Group A, 6 patients (23,1%) in Group B and 2 patients (7,7%) in Group C had hemorrhage during or after treatment. Sixteen patients (6 in Group A, 8 in Group B and 2 in Group C) died during hospital admission. The mortality rate was 13,3% (8,8% for Group A, 30,7% for Group B and 7,7% for Group C, respectively) in the acute phase. A favorable outcome (mRS 0–2) at the first three months after stroke was only observed in 43,3% of patients (44,1% in Group A, 46,7% in Group B and 36,4% in Group C). The average Barthel index was 72,3 in Group A, 84,4 in Group B and 56,8 in Group C (total score: 71,0).

Conclusion

Conclusion. The stroke treatment with tirofiban is safe in AIS. A large randomized controlled trial in the future will be needed to decrease the minor bleeding complication of tirofiban therapy.

тирофибанострый ишемический инсультбезопасностьTirofibanacute ischemic strokesafetyReferencesSuwanwela NC, Phanthumchinda K, Likitjaroen Y. Thrombolytic therapy in acute ischemic stroke in Asia: The first prospective evaluation. Clin Neurol Neurosurg 2006; 108 (6):549– 52.Suwanwela NC, Phanthumchinda K, Likitjaroen Y. Thrombolytic therapy in acute ischemic stroke in Asia: The first prospective evaluation. Clin Neurol Neurosurg 2006; 108 (6):549– 52.Nandigam K, Narayan SK, Elangovan S, et al. Feasibility of acute thrombolytic therapy for stroke. Neurol India 2003; 51 (4):470–3.Nandigam K, Narayan SK, Elangovan S, et al. Feasibility of acute thrombolytic therapy for stroke. Neurol India 2003; 51 (4):470–3.Kumar S, Rajshekher G, Prabhakar S. Platelet glycoprotein IIb/IIIa inhibitors in acute ischemic stroke. Neurol India 2008; 56 (4):399–404.Kumar S, Rajshekher G, Prabhakar S. Platelet glycoprotein IIb/IIIa inhibitors in acute ischemic stroke. Neurol India 2008; 56 (4):399–404.Siebler M, Hennerici MG, Schneider D, et al. Safety of Tirofiban in acute Ischemic Stroke: the SaTIS trial. Stroke 2011; 42 (9):2388–92.Siebler M, Hennerici MG, Schneider D, et al. Safety of Tirofiban in acute Ischemic Stroke: the SaTIS trial. Stroke 2011; 42 (9):2388–92.Ciccone A, Abraha I, Santilli I. Glycoprotein IIb-IIIa Inhibitors for Acute Ischemic Stroke. Stroke 2007. [Epub ahead of print].Ciccone A, Abraha I, Santilli I. Glycoprotein IIb-IIIa Inhibitors for Acute Ischemic Stroke. Stroke 2007. [Epub ahead of print].Haerten K, Krabbe C, Raiber M. Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice. Dtsch Med Wochenschr 2004; 129 (12):607–10.Haerten K, Krabbe C, Raiber M. Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice. Dtsch Med Wochenschr 2004; 129 (12):607–10.Bogousslavsky J, Leclerc JR. Platelet glycoprotein IIb/IIIa antagonists for acute ischemic stroke. Neurology 2001; 57 (5 Suppl 2): S53–7.Bogousslavsky J, Leclerc JR. Platelet glycoprotein IIb/IIIa antagonists for acute ischemic stroke. Neurology 2001; 57 (5 Suppl 2): S53–7.Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352 (9136): 1245–51.Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352 (9136): 1245–51.Pancioli AM, Broderick T, Brott T, et al. The Combined Approch to Lysis Utilizing Eptifibatide and rt-PA in Acute ischemic stroke: the CLEAR Stroke Trial. Stroke 2008; 39 (12): 3268–76.Pancioli AM, Broderick T, Brott T, et al. The Combined Approch to Lysis Utilizing Eptifibatide and rt-PA in Acute ischemic stroke: the CLEAR Stroke Trial. Stroke 2008; 39 (12): 3268–76.Kleinschnitz C, Pozgajova M, Pham M, et al. Targeting platelets in acute experimental stroke: Impact of glycoprotein ib, vi, and iib/iiia blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007; 115 (17): 2323–30.Kleinschnitz C, Pozgajova M, Pham M, et al. Targeting platelets in acute experimental stroke: Impact of glycoprotein ib, vi, and iib/iiia blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007; 115 (17): 2323–30.Choudhri TF, Hoh BL, Zerwes HG, et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting gp iib/iiia receptor-mediated platelet aggregation. J Clin Invest 1998; 102 (7): 1301–10.Choudhri TF, Hoh BL, Zerwes HG, et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting gp iib/iiia receptor-mediated platelet aggregation. J Clin Invest 1998; 102 (7): 1301–10.Moriguchi A, Maeda M, Mihara K, et al. Fk419, a novel nonpeptide gpiib/iiia antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: Comparison with tirofiban. J Cereb Blood Flow Metab 2005; 25 (1): 75–86.Moriguchi A, Maeda M, Mihara K, et al. Fk419, a novel nonpeptide gpiib/iiia antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: Comparison with tirofiban. J Cereb Blood Flow Metab 2005; 25 (1): 75–86.Maeda M, Moriguchi A, Mihara K, et al. Fk419, a nonpeptide platelet glycoprotein iib/iiia antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: Comparison with tissue plasminogen activator. J Cereb Blood Flow Metab 2005; 25 (1):108–18.Maeda M, Moriguchi A, Mihara K, et al. Fk419, a nonpeptide platelet glycoprotein iib/iiia antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: Comparison with tissue plasminogen activator. J Cereb Blood Flow Metab 2005; 25 (1):108–18.Coller BS. Binding of abciximab to alpha v beta 3 and activated alpha m beta 2 receptors: With a review of platelet-leukocyte interactions. Thromb Haemost. 1999; 82 (2): 326–36.Coller BS. Binding of abciximab to alpha v beta 3 and activated alpha m beta 2 receptors: With a review of platelet-leukocyte interactions. Thromb Haemost. 1999; 82 (2): 326–36.Murphy JF, Bourdet JC, Wyler B, et al. The vitronectin receptor (alpha v beta 3) is implicated, in coorperation with p-selectin and platelet-activating facotr, in the adhesion of monocytes to activated endothelial cells. Biochem J 1994; 304 (Pt2): 537–42.Murphy JF, Bourdet JC, Wyler B, et al. The vitronectin receptor (alpha v beta 3) is implicated, in coorperation with p-selectin and platelet-activating facotr, in the adhesion of monocytes to activated endothelial cells. Biochem J 1994; 304 (Pt2): 537–42.Molina CA, Alvarez-Sabin J, Montaner J, et al. Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke 2002; 33 (6): 1551–6.Molina CA, Alvarez-Sabin J, Montaner J, et al. Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke 2002; 33 (6): 1551–6.Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107 (4):598–603.Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107 (4):598–603.Mangiafico S, Cellerini M, Nencini P, et al. Intravenous glycoprotein iib/iiia inhibitor (tirofiban) followed by intra-arterial urokinase and mechanical thrombolysis in stroke. AJNR Am J Neuroradiol 2005; 26 (10): 2595–601.Mangiafico S, Cellerini M, Nencini P, et al. Intravenous glycoprotein iib/iiia inhibitor (tirofiban) followed by intra-arterial urokinase and mechanical thrombolysis in stroke. AJNR Am J Neuroradiol 2005; 26 (10): 2595–601.Junghans U, Seitz RJ, Aulich A, et al. Bleeding risk of tirofiban, a nonpeptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study. Cerebrovasc Dis 2001; 12 (4):308–12.Junghans U, Seitz RJ, Aulich A, et al. Bleeding risk of tirofiban, a nonpeptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study. Cerebrovasc Dis 2001; 12 (4):308–12.Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002; 59 (6): 862–7.Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002; 59 (6): 862–7.

The authors declare that there are no conflicts of interest present.